ARID1B

Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update

Retrieved on: 
Montag, Mai 6, 2024
Chromatin, Protein, SMARCA4, BRG1, Security, Research, SMARCA2, IND, Prostate cancer, LDAC, Acetyltransferase, BRM, AACR, Lung cancer, Multiple myeloma, AML, CBP, ARID1B, Lilly, Complex, Merck, NSCLC, DLBCL, ARID1A, Survival, Thrombocytopenia, Therapy, Gene expression, Biology, Cancer, Prostate, Data, Patient, Selective, SWI/SNF, Neoplasm, MDS, Anemia, Pharmaceutical industry

In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.

Key Points: 
  • In April 2024, Foghorn presented preclinical data highlighting pipeline progress from multiple potential first-in-class medicines, including the first presentation of preclinical data for FHD-909, at the 2024 American Association for Cancer Research (AACR) Annual Meeting held April 5-10, 2024.
  • In April 2024, Foghorn hosted the first Future of Disease and Chromatin Regulation Summit at the Foghorn corporate headquarters in Cambridge, Massachusetts.
  • In April 2024, Foghorn appointed Kristian Humer as Chief Financial Officer.
  • In April, Foghorn presented new pharmacodynamic and pharmacokinetic preclinical data at the 2024 AACR Annual Meeting highlighting:
    No observed thrombocytopenia in vivo.

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook

Retrieved on: 
Donnerstag, März 7, 2024
EP300, NSCLC, Merck, Research, AML, Neoplasm, ARID1B, Investment, CBP, Cancer, Prostate, AACR, Factorization of polynomials, Lung cancer, Safety, MDS, Collaboration, Gene expression, Thrombocytopenia, Lilly, Medicine, Patient, Survival, IND, LDAC, Development, Colorectal cancer, BRM, Chromatin, Prostate cancer, Pharmaceutical industry

“In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.

Key Points: 
  • “In 2023 we initiated a combination study with FHD-286 in AML, with data anticipated in the second half of 2024.
  • The IND is planned for the second quarter of 2024, with an initial focus in non-small cell lung cancer.
  • The Company is conducting preclinical work to further explore the opportunity and expects data in the second quarter of 2024.
  • Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting, April 5-10, 2024.

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024

Retrieved on: 
Montag, Januar 8, 2024
LDAC, Medicine, IND, Colorectal cancer, EGFR, BRG1, Prostate cancer, Factorization of polynomials, MDS, Thrombocytopenia, Gene expression, Chromatin, Neoplasm, Prostate, CBP, Cancer, Patient, Safety, ARID1B, AML, NSCLC, BRM, EP300, Pharmaceutical industry

This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.

Key Points: 
  • This will also include preclinical combination data of FHD-286 with tyrosine kinase inhibitors of EGFR and KRAS.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • This is all supported by our cash and equivalents position of approximately $259.9 million as of September 30, 2023.”
    FHD-286.
  • Foghorn is engaged in a strategic collaboration with Loxo@Lilly and continues to advance the BRM selective inhibitor and degrader programs along with other undisclosed programs.

Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update

Retrieved on: 
Donnerstag, November 2, 2023
Research, NSCLC, EP300, IND, Thrombocytopenia, MDS, Preclinical development, Colorectal cancer, Merck, Chromatin, Factorization of polynomials, Prostate cancer, Hanson, LDAC, ARID1B, Clinical trial, CBP, BRG1, BRM, Safety, Investment, AR, Patient, Gene expression, BAF, Prostate, Mutation, State Administrative Expenses, Cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn, AML

“During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.

Key Points: 
  • “During the third quarter, we continued to enroll patients in our FHD-286 combination study in AML and expect to have data in the second half of 2024.
  • Foghorn commenced a Phase 1 study of FHD-286 in combination with decitabine or low-dose cytarabine (LDAC) in relapsed and/or refractory AML patients, with the first patient dosed during the third quarter of 2023.
  • As of September 30, 2023, the Company had $259.9 million in cash, cash equivalents and marketable securities, which provides cash runway into the first half of 2026.
  • Net loss was $14.3 million for the three months ended September 30, 2023, compared to a net loss of $25.8 million for the three months ended September 30, 2022.

Foghorn Therapeutics Provides Second Quarter 2023 Financial and Corporate Update

Retrieved on: 
Freitag, August 4, 2023
ARID1B, Therapy, CBP, Selective, CDX, Chromatin, Clinical trial, BRM, Uveal melanoma, BRG1, Mum, Gene expression, NSCLC, EP300, Preclinical development, PDX, Science, MDS, State Administrative Expenses, AML, Merck & Co., BAF, Lilly, Patient, Investment, LDAC, Biology, Research, IND, Factorization of polynomials, Safety, Prostate cancer, Pharmaceutical industry, Vaccine, Decitabine, Foghorn

CAMBRIDGE, Mass., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended June 30, 2023. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • “Foghorn made important progress across both our clinical and preclinical pipeline in the second quarter.
  • We are on track to initiate dosing in a combination study of FHD-286 in AML in the third quarter.
  • On June 28, 2023, Foghorn announced data from the Phase 1 dose escalation safety study of FHD-286 in metastatic uveal melanoma (mUM).
  • As of June 30, 2023, the Company had $284.3 million in cash, cash equivalents and marketable securities, which provides a cash runway into the second half of 2025.

Foghorn Therapeutics Provides First Quarter 2023 Financial and Corporate Update

Retrieved on: 
Montag, Mai 8, 2023
Synovial sarcoma, ARID1B, Therapy, CBP, Selective, Chromatin, BRM, Uveal melanoma, BRG1, Mum, Gene expression, NSCLC, Lung cancer, EP300, Science, MDS, State Administrative Expenses, AML, Merck & Co., BAF, Lilly, Patient, Investment, Data, Biology, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, IND, Conference, Factorization of polynomials, Food, Prostate cancer, Pharmaceutical industry, Cryptocurrency, Foghorn

Top-line Phase 1 safety and efficacy data is expected in the second quarter of 2023.

Key Points: 
  • Top-line Phase 1 safety and efficacy data is expected in the second quarter of 2023.
  • The Company anticipates providing a regulatory update for FHD-286 in AML/MDS in the second quarter of 2023.
  • On April 24, 2023, Foghorn provided an update on the FHD-609 Phase 1 program in synovial sarcoma and SMARCB1-deleted tumors.
  • In 2023, Foghorn will continue to utilize its Gene Traffic Control platform to discover and develop novel therapeutics under the collaboration based on disruptors of a specified transcription factor target.

Foghorn Therapeutics Provides 2023 Outlook and Full Year 2022 Corporate Update

Retrieved on: 
Donnerstag, März 9, 2023
Fred Hutchinson Cancer Research Center, Survival, Mutation, Merck, Research, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Malignancy, Prostate cancer, Food, Senior, ARID1A, Drug discovery, Therapy, Breast, BAF, EP300, Selective, IND, Acute leukemia, Myelodysplastic syndrome, Chromatin, Lung cancer, BRM, CREB, Mum, Gene expression, Lymphoma, CBP, Investment, Development, ARID1B, Ionis Pharmaceuticals, Synovial sarcoma, BRG1, Cancer, NSCLC, AML, Trial of the century, MDS, Uveal melanoma, Collaboration, Patient, State Administrative Expenses, Lilly, BRD9, Lung, Leukemia, Factorization of polynomials, Safety, Pharmaceutical industry, Vaccine, Cryptocurrency, Foghorn

CAMBRIDGE, Mass., March 09, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today provided a corporate update including the Company’s 2023 strategic priorities and 2022 key achievements in conjunction with its 10-K filing for the year ending December 31, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • “2022 was a productive year for Foghorn as we made significant progress advancing our robust preclinical and clinical pipeline,” said Adrian Gottschalk, President and Chief Executive Officer of Foghorn.
  • In 2023, Foghorn will continue to leverage its Gene Traffic Control platform to discover and develop novel therapeutics based on disruptors of an undisclosed transcription factor target.
  • In 2022, Foghorn announced Steven Bellon, Ph.D., former Senior Vice President of Drug Discovery, was promoted to Chief Scientific Officer.
  • During 2022, Foghorn announced the election of B. Lynne Parshall, Esq., and Thomas J. Lynch Jr., M.D., to its Board of Directors.

Foghorn Therapeutics Highlights Recent Clinical and Research Progress and Provides Strategic Objectives for 2023

Retrieved on: 
Montag, Januar 9, 2023
Synovial sarcoma, MDS, Gene expression, Myelodysplastic syndrome, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Lilly, Cancer, Merck, AML, Trial of the century, Safety, Precision medicine, FDA, CBP, BRM, Postcholecystectomy syndrome, Biology, Factor X, Food, ARID1B, Therapy, Mum, Patient, Observation, BRD9, Retinoic acid syndrome, Chromatin, Pharmaceutical industry, Vaccine, Cryptocurrency, Foghorn, Grand Street station (IND Sixth Avenue Line)

Mr. Gottschalk continued, “Foghorn is a leader in targeting chromatin biology, which has unique potential to address underlying dependencies of many genetically defined cancers.

Key Points: 
  • Mr. Gottschalk continued, “Foghorn is a leader in targeting chromatin biology, which has unique potential to address underlying dependencies of many genetically defined cancers.
  • Over the next four years, we anticipate the filing of at least six new INDs, reflecting the productivity of our precision medicine platform.
  • Initial Phase 1 clinical data is expected in the first half of 2023.
  • The Company anticipates providing clarity on the development path for FHD-286 in AML/MDS in the first half of 2023.

Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update

Retrieved on: 
Dienstag, August 9, 2022
MDS, U.S. Securities and Exchange Commission, Trial of the century, GLOBE, Cancer, Clinical trial, Security (finance), Blood, Synovial sarcoma, Patient, ARID1B, BRM, ATPase, Development, Choroid, Food, Iris, BRD9, Sarcoma, Food and Drug Administration Amendments Act of 2007, Merck, BAF, Lilly, Ciliary body, Acute leukemia, Ligament, Nasdaq, Chromatin, Uveal melanoma, Forward-looking statement, AML, BRG1, Myelodysplastic syndrome, Cell, Bone marrow, Postcholecystectomy syndrome, Mum, FDA, Acute myeloid leukemia, State Administrative Expenses, Retinoic acid syndrome, Gene expression, Achievement, Company, Twitter, Therapy, Adult, Economics, Protein, LinkedIn, Administration, Medical imaging, Pharmaceutical industry, Cryptocurrency, Vaccine, Dietary supplement, Foghorn, Research

CAMBRIDGE, Mass., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a financial and corporate update in conjunction with the Company’s 10-Q filing for the quarter ended June 30, 2022. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • Collaboration revenues were $4.5 million for the second quarter of 2022 compared to $0.3 million the second quarter of 2021.
  • Research and Development Expenses.Research and development expenses were $26.0 million for the second quarter of 2022 compared to $18.6 million for the second quarter of 2021.
  • General and Administrative Expenses.General and administrative expenses were $7.7 million for the second quarter of 2022, compared to $4.9 million for the second quarter of 2021.
  • Net Loss.Net loss was $27.3 million for the second quarter of 2022 compared to a net loss of $23.1 million for the second quarter of 2021.

Foghorn Therapeutics Provides Full Year 2021 Corporate Update and 2022 Outlook

Retrieved on: 
Donnerstag, März 10, 2022
Nasdaq, Mum, Clinical trial, Â, Choroid, Cost sharing, Chromatin, Ciliary body, BAF, Company, Ligament, Research, U.S. Securities and Exchange Commission, Gottschalk, BRD9, Iris, Cell, Sarcoma, AML, Cancer, 23rd Street station (IND Eighth Avenue Line), Mutation, Economics, Synovial sarcoma, MDS, Adult, Bone marrow, Acute leukemia, ARID1A, GLOBE, BRM, Gene expression, Acute myeloid leukemia, Security (finance), ATPase, Blood, Myelodysplastic syndrome, BRG1, Therapy, Lilly, Neoplasm, Program, ARID1B, Forward-looking statement, NSCLC, Protein, Fine chemical, Cryptocurrency, Pharmaceutical industry, Vaccine, Dietary supplement, Foghorn

CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today provided a corporate update including the Company’s 2021 key achievements and 2022 strategic priorities in conjunction with its 10-K filing for the year ended December 31, 2021. With an initial focus in oncology, Foghorn’s Gene Traffic Control® Platform and resulting broad pipeline has the potential to transform the lives of people suffering from a wide spectrum of diseases.

Key Points: 
  • In January 2022, Foghorn added Dannette Daniels as our Vice President, Protein Degrader Platform, continuing our investment in and expansion of our protein degrader capabilities.
  • In December 2021, Foghorn and Lilly announced a strategic collaboration for novel oncology targets using Foghorns proprietary Gene Traffic Control Platform.
  • In December 2021, Foghorn and Loxo Oncology at Lilly entered into a strategic collaboration for novel oncology targets.
  • Foghorn Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system.